MAGAZINE

Journal of Medical Systems

Diabetic Macular Edema Screened by Handheld Smartphone‐based Retinal Camera and Artificial Intelligence

AUTHORS & DATE

Fernando Korn Malerbi, Giovana Mendes, Nathan Barboza, Paulo Henrique Morales, Roseanne Montargil, Rafael Ernane Andrade
08/01/2024

Abstract

Background

Our aim was to assess the tomographic presence of diabetic macular edema in type 2 diabetes patients screened for diabetic retinopathy with color fundus photographs and an artificial intelligence algorithm.

Methods

Color fundus photographs obtained with a low-cost smartphone-based handheld retinal camera were analyzed by the algorithm; patients with suspected macular lesions underwent ocular coherence tomography. A total of 366 patients were screened.

Results

Diabetic macular edema was suspected in 34 and confirmed in 29 individuals, with average age $60.5 \pm 10.9$ years and glycated hemoglobin $9.8 \pm 2.4%$; use of insulin, statins, and aspirin were reported in 44.8%, 37.9%, and 34.5% of individuals, respectively; systemic blood hypertension, dyslipidemia, abdominal obesity, chronic kidney disease, and risk for diabetic foot ulcers were present in 100%, 58.6%, 62.1%, 48.3%, and 27.5% of individuals, respectively. Proliferative diabetic retinopathy was present in 31% of patients with macular edema; severity level was associated with albuminuria ($p=0.028$). Eyes with macular edema had average central macular thickness $329.89 \pm 80.98 \mu\text{m}$; intraretinal cysts, sub retinal fluid, hyper-reflective foci, epiretinal membrane, and vitreomacular traction were found in 87.2%, 6.4%, 85.1%, 10.6%, and 6.4% of eyes, respectively.

Conclusion

Diabetic retinopathy screening overwhelms health systems and is typically based on color fundus photographs, with high false-positive rates for the detection of diabetic macular edema. The present, semi-automated strategy comprising artificial intelligence algorithms integrated with smartphone-based retinal cameras could improve screening in low-resource settings with limited availability of ocular coherence tomography, allowing increased access rates and ultimately contributing to tackle preventable blindness.

Icon Button Request A QuoteRequest a Quote

Fechar

Ico Back

Later

Request a quote

Fill out the form below and we will contact you shortly.

    Ico Form Success

    Request a Quote

    Our team will contact you shortly.

    Close

    …complete suas informações

      By clicking the Complete button I allow Phelcom to contact me regarding the above request and I declare that I have read and accept the terms of Privacy Policy and Terms of Use.
      Ico Back

      Depois

      Ico Form Success

      Obrigado por completar suas informações

      FECHAR

      Ico Back

      Depois

      Solicite e comece SEU TEST DRIVE

      Por favor, preencha o formulário abaixo que entraremos em contato.

        x

        Solicitar Orçamento

        Ao clicar em Solicitar, concordo com a Política de Privacidade e os Termos de Uso, permito que a Phelcom me contate e reconheço que o Eyer é um dispositivo médico (Anvisa classe II) exigindo a supervisão de um profissional com CRM para uso e interpretação das imagens.
        Ico Form Success

        Obrigado!

        Nosso time comercial logo entrará em contato para finalizar o processo.

        FECHAR

        Ico Back

        Later

        Request more information

        Please fill out the form below and we will contact you.

          x

          Request EyerMaps

          By clicking the Request button I allow Phelcom to contact me regarding the above request and I declare that I have read and accept the terms of Privacy Policy and Terms of Use.
          Ico Form Success

          Thank you!

          Our commercial team will contact you shortly to finalize the process.Our commercial team will contact you shortly to finalize the process.
          CLOSE